1. Clinical outcomes in high‐hypoglycaemia‐risk patients with type 2 diabetes switching to insulin glargine 300 U/mL versus a first‐generation basal insulin analogue in the United States : Results from the DELIVER High Risk real‐world study. Issue 1 (22nd November 2021) Authors: Sullivan, Sean D.; Freemantle, Nick; Gupta, Rishab A.; Wu, Jasmanda; Nicholls, Charlie J.; Westerbacka, Jukka; Bailey, Timothy S. Journal: Endocrinology, diabetes & metabolism Issue: Volume 5:Issue 1(2022) Page Start: n/a Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Comparable glycaemic control and hypoglycaemia in adults with type 2 diabetes after initiating insulin glargine 300 units/mL or insulin degludec: The DELIVER Naïve D real‐world study. Issue 9 (21st June 2019) Authors: Sullivan, Sean D.; Nicholls, Charlie J.; Gupta, Rishab A.; Menon, Arjun A.; Wu, Jasmanda; Westerbacka, Jukka; Bosnyak, Zsolt; Frias, Juan P.; Bailey, Timothy S. Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 9(2019) Page Start: 2123 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Early hypoglycaemia and adherence after basal insulin initiation in a nationally representative sample of Medicare beneficiaries with type 2 diabetes. Issue 11 (11th August 2019) Authors: Li, Pengxiang; Geng, Zhi; Ladage, Vrushabh P.; Wu, Jasmanda; Lorincz, Ilona; Doshi, Jalpa A. Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 11(2019) Page Start: 2486 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. How many people with type 2 diabetes fulfil the eligibility criteria for randomized, controlled trials of insulin glargine 300 U/mL in a real‐world setting?. Issue 3 (18th December 2020) Authors: Mauricio, Dídac; Westerbacka, Jukka; Nicholls, Charlie; Wu, Jasmanda; Gupta, Rishab; Eliasson, Björn Journal: Diabetes, obesity & metabolism Issue: Volume 23:Issue 3(2021) Page Start: 838 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Risk of Wernicke's encephalopathy and cardiac disorders in patients with myeloproliferative neoplasm. Issue 2 (April 2015) Authors: Wu, Jasmanda; Zhang, Ling; Vaze, Anjali; Lin, Stephen; Juhaeri, Juhaeri Journal: Cancer epidemiology Issue: Volume 39:Issue 2(2015) Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Switching to insulin glargine 300 units/mL in real‐world older patients with type 2 diabetes (DELIVER 3). Issue 11 (18th July 2019) Authors: Bailey, Timothy S.; Wu, Jasmanda; Zhou, Fang L.; Gupta, Rishab A.; Menon, Arjun A.; Berhanu, Paulos; Westerbacka, Jukka; Van Vleet, John; Blonde, Lawrence Journal: Diabetes, obesity & metabolism Issue: Volume 21:Issue 11(2019) Page Start: 2384 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Use of real‐world evidence in regulatory decisions for rare diseases in the United States—Current status and future directions. Issue 10 (30th January 2020) Authors: Wu, Jasmanda; Wang, Cunlin; Toh, Sengwee; Pisa, Federica Edith; Bauer, Larry Journal: Pharmacoepidemiology and drug safety Issue: Volume 29:Issue 10(2020) Page Start: 1213 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗